Proteotech Inc.

Other

Beth P Nguyen

Alan D Snow

Gerardo M Castillo

Thomas P Lake

Virginia J Sanders

Lesley Larsen

Stephen D Lorimer

David Samuel Larsen

Rex T Weavers

David Llewellyn Coffen

Charlotte Coffen, Legal Representative

Paula Y Choi

Manfred Weigele

Qubai Hu

Judy Cam

Joel A Cummings

David S Larsen

D Snow Alan

Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus. The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.

Isolation, purification and synthesis of procyanidin B2 and uses thereof

The use of 3,4,3',4&#x2032;-tetrahydroxychalcone in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease

Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease.

Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease

A pharmaceutical composition comprising a peptide consisting of Arg-Val-Ala-Val-Ile-Met-Gly-amide-having at least one D-amino acid.

Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders

Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis

A pharmaceutical composition comprising peptide Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D-amino acid.

Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders

Assay-guided affinity fractionation and reverse phase high pressure liquid chromatography (HPLC) methodology to isolate, test and characterize the most active water-soluble ingredients within Cat's Claw, or. These components appear to account for the majority of the amyloid or A&#x3b2; fibrillogenesis inhibitory activity. Individual fractions and/or compounds as isolated by HPLC are tested in relevant in vitro and/or animal models, and found to consistently demonstrate inhibition of amyloid or A&#x3b2; fibrillogenesis. Related extraction methods are disclosed.

[object Object]

A pharmaceutical composition, or pharmaceutical agent for treating A&#x3b2; amyloidosis in a patient that has at least one laminin-derived peptide or fragment thereof from the group D-A13, D-HA3G76, D-A4G82, D-A5G81, D-A5G101, D-HA3G47, D-HA3G58, D-HA3G74, D-HA3G83, D-A5G82, D-R-AG73, D-R-A13, D-R-HA3G76, D-R-A4G82, and D-R-A5G81.

Growing community of inventors

Bothell, WA, United States of America

Beth P Nguyen